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Abstract
A correct identification of seropositive individuals for the severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is of para-
mount relevance to assess the degree of protection of a human popula-
tion to present and future outbreaks of the COVID-19 pandemic. We
describe here a sensitive and quantitative flow cytometry method using
the cytometer-friendly non-adherent Jurkat T-cell line that stably
expresses the full-length native spike “S” protein of SARS-CoV-2 and a
truncated form of the human EGFR that serves a normalizing role. S
protein and huEGFRt coding sequences are separated by a T2A self-
cleaving sequence, allowing to accurately quantify the presence of anti-
S immunoglobulins by calculating a score based on the ratio of fluores-
cence intensities obtained by double-staining with the test sera and
anti-EGFR. The method allows to detect immune individuals regardless
of the result of other serological tests or even repeated PCR monitoring.
As examples of its use, we show that as much as 28% of the personnel
working at the CBMSO in Madrid is already immune. Additionally, we
show that anti-S antibodies with protective neutralizing activity are
long-lasting and can be detected in sera 8 months after infection.
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Introduction
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is
the causative agent of the global pandemic COVID-191. Phylogenetic
analysis of the full genome classifies SARS-CoV-2 as a Betacoron-
avirus subgenus Sarbecovirus, lineage B and is related to bat
isolates of SARS-CoV and is 79% identical to the SARS virus causing
a viral epidemic in 2002 (Lu et al, 2020). Like other coronaviruses,
SARS-CoV-2 encodes for 16 non-structural proteins at the 50 end of
the genomic RNA and structural proteins spike (S), envelope (E),
membrane (M), and nucleocapsid (N) at the 30 end (Su et al, 2016).
The spike S protein is responsible for binding to ACE2 in host cells
which seems to be the main cellular receptor for the virus (Hoff-
mann et al, 2020). In native state, the S protein forms homotrimers
and is composed of two fragments S1 and S2 that result from prote-
olytic cleavage of S upon ACE2 binding (Walls et al, 2020). The S1
fragment contains a central RBD sequence that is the actual ACE2-
binding sequence and the target of neutralizing antibodies such as
those described to neutralize SARS-CoV-1.
Diagnosis of active infection is currently carried out by PCR ampli-
fication of viral RNA comprising fragments of the N, E, S, and RdRP
genes from biological samples taken from bronchoalveolar lavage
(BAL), sputum, nasal swabs, pharyngeal swabs, and fibronchoscope
brush biopsies, with the highest positive rate resulting from PCR of
BAL samples (Venter & Richter, 2020). Positivity in the PCR test
vanishes as the infection is resolved although viral RNA shedding and
PCR positivity could take place even after there is no further produc-
tion of infective virions and therefore possibility of transmission.
Unlike PCR-based tests, serological tests are not highly valuable
to determine which individual has an active infection with SARS-
CoV-2 but are key in epidemiology and Public Health policies since
it can provide an estimate of what segment of a population has been
infected with the virus and is likely to have acquired total or
partial immunity against ongoing and future resurgences of the
pandemics. Herd immunity achieved either by natural infection or
as a consequence of vaccination is a goal for all health authorities in
the world.
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Seropositivity is usually established by detecting the presence of
viral antigen-specific IgG or IgM in the serum of individuals using
recombinant fragments of the S or N proteins and tests based on
ELISA or lateral flow assay (Venter & Richter, 2020; Weissleder
et al, 2020). A disadvantage of those tests is that neutralizing anti-
bodies are not directed against the N protein and that recombinant
fragments of S miss the quaternary structure of the S protein trimer,
which is the native form of the spike protein in the viral envelope.
Therefore, part of the neutralizing antibodies directed against the
native S trimer could be missed in serological tests based on the
expression of recombinant proteins.
Flow cytometry of cells that are transfected with vectors that
express the S protein represents an attractive alternative strategy for
serological tests. This strategy allows detection of antibodies against
the native form of the S protein. Such system has been used by tran-
sient transfection of HEK293T human cells to analyze different
cohorts of COVID-19 patients (Grzelak et al, 2020). We have devel-
oped here a flow cytometry serological test using stably transfected
Jurkat, a human leukemic T-cell line, that co-expresses the native S
protein of SARS-CoV-2 and a truncated form of the human EGFR
that serves as a normalizer. The Jurkat-S system is amenable to
standardization and can be used for multiplexed detection of human
immunoglobulins of all isotypes in a single assay. Finally, we show
that the system is superior to ELISA-based methods to detect sera of
donors containing neutralizing antibodies.
Results
We used a lentiviral vector to express the full spike “S” protein of
SARS-CoV-2 followed by a truncated human EGFR protein
(huEGFRt) linked by a T2A self-cleaving sequence in transduced
cells (Fig 1A). This system allows expression of the two proteins
from a monocistronic mRNA. We produced transducing super-
natants to express the construct in the human leukemic cell line
Jurkat. Taking advantage of the fact that after cleavage the T2A
sequence remains attached to the N-terminal protein, we studied
whether the S protein was expressed at the cell surface of the
transduced Jurkat cells (from now on, Jurkat-S cells). To this end,
cell surface membrane proteins of Jurkat-S cells were surface
biotinylated followed by immunoprecipitation with anti-T2A, SDS–
PAGE, and Western blot with streptavidin–peroxidase. This showed
the presence of a polypeptide of ~ 120 kD when resolved by SDS–
PAGE under reducing conditions in Jurkat-S cells but not in the
parental cells (Fig 1B). Interestingly, larger sizes of the immune-
reactive polypeptide were resolved in the absence of reducing
agents under non-denaturing conditions (i.e., without boiling;
Fig 1C). These data suggest that the S protein of SARS-CoV-2 could
be expressed on Jurkat-S plasma membrane as native homotrimers.
To determine whether the S protein expressed on Jurkat-S cells was
functional, we analyzed if it could promote the formation of syncy-
tia when Jurkat-S cells were co-incubated with the ACE2-expressing
human hepatocarcinoma cell line HepG2. We labeled Jurkat-S cells
with the green dye CFSE and HepG2 with the far red dye Cell Trace
Far Red (CTFR). After overnight incubation, we detected a Jurkat-S
dose-dependent formation of mixed cells that were not detected
when HepG2 were incubated with parental Jurkat cells not express-
ing the S protein (Fig 1D). To determine whether the mixed cells
labeled with CFSE and CTFR were syncytia and not just cell doub-
lets, the dual color cell population was sorted and seeded on cover-
slips for confocal microscopy analysis. The sorted population was
formed by large cells with multiple nuclei that were stained with
CFSE and CTFR, demonstrating that they were syncytia formed by
fusion of Jurkat-S and HepG2 cells (Fig 1E). These data indicated
that the S protein expressed in Jurkat-S cells has fusogenic activity
and therefore that it must be in a native conformation.
The Jurkat-S cells were analyzed using a flow cytometry (FC)
assay, where staining with an anti-EGFR monoclonal antibody
detects and quantitates expression of the huEGFRt construct along-
side detection and quantitation of anti-S protein antibodies within
sera from SARS-CoV-2-infected blood donors. Figure 1F shows
Jurkat-S cells stained with anti-EGFR mAb and either a serum
sample taken from an individual before the COVID-19 pandemics
(pre-COVID-1 serum) or serum taken from an asymptomatic donor
(donor #15) determined positive with multiple serological assays
(Table EV1). Serum from donor #15 could strongly detect the S
protein expressed on Jurkat-S cells, whereas pre-COVID-1 serum did
not, proving this method to be valid for capture and detection of
anti-spike antibodies present in sera from SARS-CoV-2-exposed indi-
viduals. This assay was highly sensitive and detected anti-S protein
▸Figure 1. Jurkat-S cells expressing native SARS-CoV-2 spike S protein allow the detection of anti-S protein antibodies in human sera.A Lentiviral construct used to permanently express S protein in Jurkat. The full-length mature S protein is preceded by a leader sequence of GM-CSF and followed by a
T2A sequence which is followed by a tail-less truncated human EGFR construct.
B Expression of S protein on the plasma membrane of Jurkat-S cells assessed by surface biotinylation and followed by immunoprecipitation with anti-T2A, SDS–PAGE
under reducing conditions, and Western blot with streptavidin–peroxidase. Biotinylation of the parental Jurkat cells was carried out in parallel as a negative control.
The arrow indicates the position of the reduced S protein.
C Expression of the S protein in native form was assessed by surface biotinylation of Jurkat-S and Jurkat cells followed by immunoprecipitation with anti-T2A followed
by SDS–PAGE under non-denaturing conditions (i.e., without reducing agents and without boiling). The nitrocellulose membrane was blotted with streptavidin–
peroxidase. Arrows point at different oligomerization forms of the S protein.
D Formation of syncytia between the CTFR-labeled ACE2+ human cell line and the CFSE-labeled Jurkat-S cells was measured by flow cytometry by analyzing the
percentage of cells that become double positive for CTFR and CFSE markers. The bar plot to the right shows the effect of different doses of HepG2 cells on the
formation of syncytia with a fixed number of Jurkat. Parental Jurkat cells (not expressing S protein) are considered negative controls. Data represent the mean  SD
of triplicated datasets.
E Formation of syncytia between the CTFR-labeled ACE2+ human cell line and the CFSE-labeled Jurkat-S cells, in an experiment as in (D), was confirmed by confocal
microscopy after sorting cells double positive for CTFR and CFSE. Nuclei were identified by DAPI staining. Red arrowhead in the DAPI image indicates a nucleus of
Hep-G2 origin; the green arrowhead the nucleus of Jurkat-S origin.
F Overlay plot of Jurkat-S cells that were incubated with anti-EGFR mAb conjugated to Bv421 and serum from either donor #15 or from a pre-COVID-19 donor and
followed by a secondary anti-human IgG1 antibody conjugated to PE.
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antibodies over a wide range of mean fluorescence intensities (MFI)
when staining with sera from different blood donors (Fig 2A). In
comparison with commercial serological assays, this Jurkat-S
clone FC assay detected more cases of seropositive individuals
(Table EV1) and facilitated verification of positive seroconversion in
patient samples that had previously given uncertain results (Fig 2B,
orange symbols).
In order to compare the sensitivity of our Jurkat-S assay with a
conventional ELISA, we used recombinant Spike proteins, specifi-
cally the S1 and receptor binding domain (RBD) fragments, both
kind gifts from Dr. Peter Cherepanov (CRICK, London). We coated
the plates with 2 µg/ml of either S1 or RBD and incubated the
coated plates with a 1:50 dilution of human sera. Binding of human
IgG1 antibodies was detected using a peroxidase-labeled anti-human
IgG1 monoclonal antibody. Comparing absorbance values from the
ELISA with MFI values of the Jurkat-S FC assay across sera stratified
by experienced COVID-19 symptoms (asymptomatic, mild, moder-
ate, moderate–severe, and severe) showed the MFI values to be
spread across a wider range of values than absorbance values
(Fig 3A). Finally, the comparison of absorbance values in the two
ELISA tests (anti-S1 and anti-RBD) produced a good-fitted straight
line (R2 = 0.83; Fig 3B), whereas the comparison of the FC MFI with
the absorbance values (against S1 and RBD) poorly adjust to a
straight line (R2 = 0.55 and R2 = 0.32; Fig 3B), with samples that
gave a poor signal in the ELISA giving a clear signal with the FC
assay. This indicates that detecting S-specific IgG1 using the Jurkat-
S FC assay increases sensitivity for detecting SARS-CoV-2-exposure
in individuals testing negative by ELISA. These individuals may
have generated antibodies against other fragments of the Spike, e.g.
S2 (Ng et al, 2020), or against the native trimeric structure of the S
protein, that are found on the surface of Jurkat-S cells but not in the
ELISAs. For example, sera from donors #8, #46, #48, and #49 were
apparently negative for anti-S IgG1 by ELISA but clearly positive by
FC with Jurkat-S. By contrast, anti-S IgG1 was detected in sera from
donors #15, #31, and #52 by both ELISA and FC, and serum from
donor #58, appeared to be detected better by ELISA than by FC
(Fig 3B). To determine whether those differences were maintained
at different dilutions of the sera, a titration test was carried out in
parallel using the FC Jurkat-S method and ELISA of the S1 fragment.
The results showed that all sera, including that of donor #58, were
clearly positive by FC, even at a 1:450 dilution, whereas by ELISA,
sera #8, #46, #48, and #49 remained negative (Fig 3C). These results
indicate that sera, which could have been considered negative by
ELISA, are indeed positive for S-specific IgG1 by FC with Jurkat-S.
Sample #49 was from an asymptomatic individual but sera #8, #46,
and #48 were from individuals who had experienced symptoms that
ranged from mild to severe (Table EV1).
To determine which of the two methods, ELISA or FC, was
producing a more reliable picture of the immune status of the serum
donors, we assayed sera testing positive by FC and negative by
ELISA for the capacity to neutralize S protein function. We gener-
ated pseudotyped lentiviral reporter particles coated either with the
S protein of SARS-CoV-2 or, as a control, with the G protein of VSV
virus (Fig 4A). To test the functionality of the viral particles, they
were used to transduce HEK293T cells stably transfected with ACE2
in the presence of different dilutions of serum from donor #66, that
was identified as positive by the FC method (Table EV1), o from the
pre-COVID-1 donor. Serum #66 neutralized the entry of the S
protein-pseudotyped lentivirus in a dose-dependent manner,
whereas the pre-COVID-1 serum did not (Fig 4B). The effect of the
#66 serum was due to specifically neutralizing the S protein since
this serum did not inhibit transduction of ACE2+ HEK293T cells by
lentivirus pseudotyped with VSV G protein (Fig 4B). We then inter-
rogated whether sera from donors #46 and #48, testing positive by
FC but not by ELISA (Fig 3C), were also able to neutralize the S
protein-pseudotyped lentivirus. They did inhibit (Fig 4C), suggest-
ing that these serum samples contain neutralizing antibodies and
therefore that the Jurkat-S FC assay can be superior to ELISA for
detecting protective immunity to SARS-CoV-2.
To further determine the capacity of the FC Jurkat-S method to
determine seropositivity in samples scored as negative by other
methods, we tested serum samples collected between March and
May 2020, from 30 healthcare workers (Hospital Ramon y Cajal,
Madrid) that were repeatedly tested by PCR and ELISA for SARS-
CoV-2 and determined to be negative in both tests (Table EV2).
These samples were re-screened using the Jurkat-S FC assay and
two sera (RyC52 and RyC65) resulted clearly positive for S-specific
IgG1 (Fig 4D). To increase the sensitivity for detecting S-specific
IgG1 in sera giving S/EGFR MFI ratios close to the 0.5 threshold for
positivity, we plotted the EGFR MFI vs S protein MFI (Fig 4E) such
as it was done in Fig 1F. S protein expression in Jurkat-S is coupled
to huEGFRt expression (Fig 1A), thus positive sera produce a diago-
nal MFI on a plot of anti-S protein vs EGFR, whereas negative serum
generates a flat profile. An example of this can be seen in Fig 4E
with borderline sera RyC58 and RyC70. To further refine the method
and establish a clear positive/negative threshold, we calculated an
algorithm based on slope after fitting the distribution of anti-EGFR
and anti-S fluorescence intensities to a Gaussian distribution (Mate-
rials and Methods and Fig EV1). The algorithm takes into account
two mean points (the centers of the two Gaussian distributions) and
the shape of the curves, defined by the co-variance matrixes (four
parameters, Materials and Methods section). The result is a Score
value with a threshold of 0.024 as the limit between positive and
negative samples. Plotting the Score vs the S/EGFR MFI ratios for
the 30 RyC samples results in a straight line (Fig 4F) and identifies
samples RyC46 and RyC56 (in addition to the previously identified
RyC52, RyC58, and RyC65 samples, Fig 4E) as positive. We carried
out a neutralization assay with the S protein-pseudotyped lentivirus
▸Figure 2. Flow cytometry of Jurkat-S cells allows to detect anti-S immunoglobulins poorly detected by commercial tests with a wide dynamic range.A Overlay histograms of Jurkat-S staining with different human sera diluted 1:50. A pre-COVID-19 serum sample is taken as negative control (gray histogram).
B Bar plots of flow cytometry data generated with Jurkat-S cells and the panel of serum samples of Table EV1 classified according to their result in the indicated
commercial tests: green, positive for the test; orange, weak, or unclear; magenta, negative samples. Flow cytometry data are expressed as the ratio between the MFI
of the antibody anti-S and the MFI for EGFR. Negative values for the flow cytometry test are those with a S/EGFR MFI ratio lower than 0.5. This ratio was set in order
to fit most of the data negative for the other serological tests (pink triangles) under that threshold. Data represent the mean  s.e.m. All datapoints are shown.
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and the available RyC samples that were positive by the FC method
and found a weak, although significant, neutralizing activity for
samples RyC46, RyC52, and RyC58 (Fig 4G), confirming the validity
of the FC seropositivity data.
We moved onto multiplexing the Jurkat-S FC assay for the detec-
tion of a panel of anti-S immunoglobulins, including IgG1, IgG2,
IgG3, IgG4, IgA, and IgM. We detected all anti-S isotypes in several








































6 of 15 EMBO Molecular Medicine 13: e13549 | 2021 ª 2021 The Authors
EMBO Molecular Medicine Lydia Horndler et al
most robust detection was observed for IgG1 in all cases, followed
by IgG4 and IgA (Fig EV2A). A weak IgM response, in terms of S/
egfr MFI ratio, was detected in all samples with the highest value in
sample RyC65. The presence of anti-S antibodies of the IgG2 and
IgG3 subclasses was not clearly detected in all samples.
Figure EV2B shows a summary heatmap of the fold change in detec-
tion of each anti-S immunoglobulin isotype, referred to the MFI of
the pre-COVID-19 sample. This indicates that the predominant
humoral response to the S protein in the analyzed samples is in the
form of IgG1 followed by IgM and IgG4.
To validate the FC Jurkat-S method, we decided to test 52
samples kept at the Hospital de la Princesa (HUP, Madrid), of
which 40 had been determined positive by both PCR and an
ELISA antibody method (Martınez-Fleta et al, 2020) (Table EV3).
In addition, we included another set of 52 samples collected from
donors before the onset of the COVID-19 pandemics in 2019. All
HUP samples from PCR+ELISA+ patients were also positive by the
FC Jurkat-S method, giving a high Score (Fig 5A). By contrast,
none of the pre-COVID sera gave positive results above the 0.024
threshold. These data show a high-level of correlation (> 97.5%)
between samples of patients doubly identified as positive by PCR
and a serological method, and our FC Jurkat-S method. In addi-
tion, no false-positive cases were identified in the cohort of 52
pre-COVID sera. The HUP cohort also revealed the presence of
six samples tested negative by PCR that showed positive by both
ELISA and the FC Jurkat-S method and one sample of serum
from a PCR+ patient that was negative by ELISA and the FC
Jurkat-S method (Fig 5A). We interpret those discrepancies as
false PCR+ for the latter case and false PCR negative for the six
samples, probably because the samples for PCR were taken when
the viral genome was no longer detectable (Table EV3). To deter-
mine which of the results was correct, if the PCR test or the sero-
logical tests, we chose four of the conflicting samples (Fig 5B) to
be tested in the neutralization assay (Fig 4A). In spite of being
negative by PCR, sera from donors HUP53, HUP56, and HUP60
neutralized the S protein-pseudotyped lentivirus (Fig 5C) indicat-
ing that those sera contained neutralizing antibodies, thus con-
firming the seropositive result using the FC Jurkat-S method. By
contrast, serum from donor HUP59, who tested positive by PCR
(Fig 5A and B), did not exhibit any neutralizing capacity, in
agreement with the negative result in the FC Jurkat-S test. These
results suggest that donor HUP59 was either a false PCR positive
or was deficient in the development of a humoral response.
There is a controversy about the rapid decay of anti-SARS-CoV-2
antibodies, especially in persons with mild symptoms (Ibarrondo
et al, 2020; Liu et al, 2020; Terpos et al, 2020; Wang et al, 2020).
We assessed this issue by analyzing serum samples taken from
eleven donors of the CBMSO with a variety of symptoms
(Table EV4) in the months of June and October 2020, with a mean
elapsed time of 123 days. We detected minor variations in the titer
of anti-S antibodies by the FC Jurkat-S method with most donors
not undergoing a significant decrease (Fig 6A). The titer in donor
CBM-3 significantly increased in the June–October period suggesting
the possibility of a reinfection with SARS-CoV-2. Although reactivity
◀ Figure 3. Flow cytometry of Jurkat-S cells detects anti-S antibodies in sera otherwise negative for ELISA using recombinant S1 and RBD proteins.
A Box and whiskers plot of MFI and absorbance data in human sera according to their clinical classification of COVID-19 symptoms. Clinical classification was done
according to the following parameters: Asymptomatic, no symptoms; mild, three or more of the following symptoms: non-productive cough, hyperthermia, headache,
odynophagia, dyspnea, asthenia, myalgia, ageusia, anosmia, cutaneous involvement; moderate, three or more of the above symptoms plus gastrointestinal symptoms,
or more than three of the above for seven or more days; and moderate–severe, three or more of the above symptoms plus pneumonia. Box and whiskers are shown
to represent the minimum and maximum values as well as the median. All datapoints are shown.
B Comparison of MFI vs absorbance data generated by flow cytometry and ELISA for all human sera. A lineal regression curve was adjusted, with a 95% confidence
interval, to all data with the R2 values indicated in the plots. Selected samples of outliers (#4, #5, #8, #31, #46, #48, #49, and #58) as well as samples close to a
diagonal (#36, #52, and #15) are indicated.
C Titration of selected human sera by ELISA using the S1 protein and by flow cytometry with Jurkat-S cells. Samples with antibodies detected by flow cytometry and
not by ELISA are indicated (#8, #46, #48, #49). Data represent the mean  SD of duplicates. An unpaired two-tailed t-test was carried out to compare the results of
1:50, 1:150, and 1:450 dilutions of sera #8, #46, #48 and #49 by FC to the pre-COVID-1 sample as a negative control. *P < 0.05; **P < 0.005; ***P < 0.0005.
▸Figure 4. Sera not detected by ELISA but detected by flow cytometry with Jurkat-S contain neutralizing antibodies.A Cartoon of the strategy for generation of pseudotyped lentiviruses. HEK-293T cells were transfected with a lentiviral construct containing the EGFP marker gene and
two more plasmids encoding for the gag and pol genes of HIV-1 and for the S protein of SARS-CoV-2. Alternatively, the latter plasmid was replaced by another one
encoding the G protein of VSV. The cell supernatants collected after 48 h of transfection were used to transduce HEK-293T cells stably transfected with human ACE2.
B Validation of the neutralization method was carried out with cell HEK-293T cell culture supernatants containing lentiviral particles pseudotyped with either the S
protein or with the VSV G protein. The supernatants were mixed with sera from donor #66 at the indicated dilutions or from a pre-COVID sample as a control before
addition onto HEK-293T-ACE2+ cell cultures. No serum refers to a control containing no human sera. Data represent the mean  SD of triplicates.
C The presence of neutralizing antibodies in sera from donors #46 and #48 found negative by ELISA and positive by flow cytometry (Fig 3C) was demonstrated as in
panel B. Data represent the mean  SD of triplicates. *P < 0.05; **P < 0.005; ****P < 0.00005 (paired two-tailed t-test comparing all serum dilutions to the pre-
COVID sample).
D Bar plot showing the S/EGFR MFI ratio determined by flow cytometry analysis with Jurkat-S of serum samples from 30 sanitary personnel repeatedly tested as PCR
negative for SARS-CoV-2 at the Ramon y Cajal Hospital of Madrid. A negative result is considered for a ratio lower than 0.5. Two clear cases of sera positive for anti-S
IgG1 are indicated (RyC52 and RyC65). A borderline sample just above the threshold line (RyC58) is also indicated. Data show the mean  s.e.m. All datapoints are
shown.
E Two-color dot plot overlay of anti-S protein fluorescence vs EGFR fluorescence for borderline serum sample RyC58 (blue) and the clearly negative RyC70 sample (red).
The line plot to the right shows the MFI for EGFR taken at the three sectors indicated in the two-color plot and the corresponding MFI values for EGFR.
F Plot of the S/EGFR MFI ratio for the 30 RyC samples vs a Score generated according to the slope of S/EGFR and shape (see Materials and Methods and Fig EV1). The
green line indicates the threshold point (0.024) for the Score above which a serum is considered positive.
G The presence of neutralizing antibodies in sera from donors RyC46, RyC52, RyC56, and RyC58 diluted 1/15 was demonstrated as in panel B. Data represent the
mean  SD of triplicates. *P < 0.05; **P < 0.005; ****P < 0.00005 (unpaired two-tailed t-test comparing each serum to the no serum sample).
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HUP53 53 F Yes Negative Positive 0.78 0.45 Positive
HUP56 61 M Yes Negative Positive 0.95 0.45 Positive
HUP59 28 F Yes Positive Negative 0.18 -0.12 Negative
HUP60 31 F Yes Negative Positive 1.19 0.44 Positive
PCR:   + -     +     ND ND

















Figure 5. Validation of the FC Jurkat-S method.
A A total of 52 serum samples from Hospital Universitario La Princesa (HUP) and 52 samples of pre-COVID donors stored at the CBMSO were tested by the flow
cytometry method and classified according to the S/EGFR-based Score. Of the 52 HUP samples, a total of 40 were from donors testing positive by PCR and by an
ELISA test, six were from donors testing negative by PCR but positive by ELISA, one from an individual testing negative by ELISA and positive by PCR, and five were
not tested by PCR. Box and whiskers are shown to represent the minimum and maximum values as well as the median. All datapoints are shown. The broken line
indicates the threshold for a Score value of 0.024.
B, C Four HUP serum samples giving discrepant results by PCR and by the flow cytometry method were tested in the neutralization assay of pseudotyped lentivirus
(Fig 4A). Data represent the mean  SD of duplicates. *P < 0.05; **P < 0.005; ****P < 0.00005 (paired two-tailed t-test comparing all serum dilutions to the pre-
COVID sample).
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against S protein was still clearly detected in all samples taken in
October, we decided to compare the neutralization capacity of the
June and October samples of two of the donors with the highest loss
in titers (CBM-1 and CBM-2 with a 2.3- and 2.0-fold loss, respec-
tively, Fig 6A). We found a good correlation between the S/EGFR
MFI ratio in the FC Jurkat-S assay and the neutralization capacity of
the four serum samples (Fig 6B). The loss of anti-S antibody titer
was inconsequential for donor CBM-1 and both the June and Octo-
ber samples equally neutralized entry of the S-pseudotyped virus up
to a 1/4,000 dilution. Serum from donor CBM-2 experienced a small
drop in neutralization capacity between June and October from a
positivity in the neutralization test at a 1/150 dilution to a 1/50
dilution (Fig 6B). Nonetheless, those data indicate that anti-S anti-
bodies are not decaying so fast and there is still neutralization
capacity 8 months after the onset of symptoms in February 2020
(donor CBM-10, Table EV4).
In an attempt to use the FC Jurkat-S method to determine the
existence of humoral immunity to SARS-CoV-2, we analyzed a
cohort of serum samples from 415 volunteers working at the
CBMSO and collected between June and October 2020. Some of
them had been tested by PCR and/or by ELISA tests showing
discrepancies with our FC Jurkat-S test (Fig 7A). Using our neutral-
ization assay with S protein-pseudotyped virus, we found that all








































Figure 6. Evolution of the presence of anti-S antibodies between the months of June and October 2020.
A A collection of serum samples from volunteers working at the CBMSO were taken in the months of June and October 2020 and tested by flow cytometry using Jurkat-
S cells at the indicated dilutions. Flow cytometry data are shown as the S/EGFR MFI ratio. Red arrows indicate a loss in titer of antibodies between June and October,
whereas blue arrows indicate an increase in antibody titer.
B Titration of the neutralizing capacity of sera from a high titer (#66-CBM-1) and a low titer (CBM-2) donor taken in June and October 2020. The neutralization
experiment was carried out in parallel to a FC Jurkat-S test. Flow cytometry results are shown as the S/EGFR MFI ratio (right y-axis) and according to the Score value.
A plus symbol (+) indicates a Score > 0.024 for a given serum dilution; a minus symbol () indicates a Score < 0.024. Neutralization data are shown as the
percentage of HEK-293T-ACE2+ cells becoming GFP+ (left y-axis). Data represent the mean  SD of duplicates. *P < 0.05; **P < 0.005; ***P < 0.0005; ****P < 0.00005;
*****P < 0.000005 (unpaired two-tailed t-test).
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CBM-6 36 F No 2.20 0.34 Positive
CBM-11 52 F Yes Negative 1.11 0.28 Positive
CBM-12 62 F No Negative 3.58 0.34 Positive
CBM-13 28 M Yes Positive Negative 0.96 0.42 Positive
CBM-14 27 M Yes Positive Negative 0.96 0.24 Positive




Figure 7. Prevalence of seropositivity by the FC Jurkat-S method within a cohort of 415 samples.
A Discrepancies between the result of the flow cytometry test and previous PCR or ELISA tests within the CBMSO cohort.
B A neutralization assay with S protein-pseudotyped lentivirus was carried out to resolve the discrepancies. Data represent the mean  SD of duplicates. *P < 0.05;
**P < 0.005; ***P < 0.0005; *****P < 0.000005 (paired two-tailed t-test comparing all serum dilutions to the pre-COVID sample).
C Classification of the CBMSO cohort according to the Score generated from S/EGFR data. The broken line indicates the 0.024 threshold above which samples are
considered positive.
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antibodies (Fig 7B), indicating that the results of our FC test were
correct. Of the 415 samples tested, a total of 115 resulted with a
positive Score above the threshold of 0.024 (Fig 7C), indicating
that a 28% of the analyzed CBMSO population has developed
humoral immunity.
Discussion
Here, we describe a method based on flow cytometry of a human T
lymphoblastic leukemia cell line that stably expresses the S protein
of SARS-CoV-2. Compared to methods based on the use of recombi-
nant purified proteins, the FC method with Jurkat-S offers a wider
range of response and it is highly quantitative. The coordinated
expression of huEGFRt serves the function of a normalization
marker and of unambiguously determining the positivity of sera
with low antibody titers. The system can also be used in a multi-
plexed format to simultaneously detect all immunoglobulin
subclasses specific for the S protein. Importantly, it is superior to
current ELISA methods to determine the fraction of the human
population that has acquired antibody responses and neutralizing
activity toward SARS-CoV-2.
A FC-based method has been previously described using
HEK293T cells that overexpress the S protein (Grzelak et al, 2020;
Ng et al, 2020). Compared to this, the Jurkat-S system described
here offers the advantage of employing a non-adherent cell line that
does not require methods such as trypsinization to place them in
suspension. In addition, as said above, the coordinated expression
of the huEGFRt marker from a single polypeptide makes it very
convenient to resolve ambiguous samples. This property has served
to detect as seropositive 5 cases out of a cohort of 30 sanitary
personnel highly exposed to SARS-CoV-2 and repeatedly considered
as negative by PCR and other serological methods. The method has
been validated using samples from contrasted PCR+ and seroposi-
tive patients as well as sera collected before 2019. In all cases in
which there has been a discrepancy between the FC Jurkat-S
method and other serological methods, the FC method has been
backed by neutralization data using S protein-pseudotyped lentiviral
particles. The FC Jurkat-S method detects as seropositive serum
samples that actually contain neutralizing antibodies.
To ascertain the usefulness of the FC method, we have measured
the presence of anti-S antibodies in paired samples of sera taken from
the same donors within a 4-month interval. We found that the titer of
antibodies is in general stable during the studied period and remain as
long as 8 months after the reported exposure to SARS-CoV-2. Further-
more, after 8 months of exposure to the virus, sera are shown to
contain neutralizing immunity. Thus in the controversy about the
duration of effective humoral response (Ibarrondo et al, 2020; Liu
et al, 2020; Terpos et al, 2020; Wang et al, 2020), our results support
that anti-S functional neutralizing antibodies are long-lasting.
In another example, we have used the FC Jurkat-S method to
study the seroprevalence in a cohort of 415 individuals working
at the CBMSO in Madrid with samples collected between June
and October 2020. Our data show that 28% of the tested sera is
positive for antibodies against the S protein, a percentage that is
much higher than that of other studies carried out with samples
of Madrid using other serological methods (Pollan et al, 2020). It
would be interesting to use the FC method in the coming months
after the onset of the second wave of the pandemics and poten-
tially obtain a more accurate determination of seroprevalence
within the general population. Another conclusion that can be
drawn from the analysis of the Empireo and HUP cohorts (Tables
EV1 and EV3) by the FC Jurkat-S method is that the humoral
response to the S protein is not inferior for the older donors (ages
60–70 and more) than for younger ones, suggesting that age
“per se” is not conditioning the response.
Compared to ELISA and rapid serological tests, the FC Jurkat-S
method has the disadvantage of requiring the use of a flow cytome-
ter. However, the extended use of those machines in the immunol-
ogy and hematology departments of hospitals may make the method
of choice if the goal is to accurately determine what proportion of a
human population likely has a protective humoral response and how
far is from reaching the anxiously sought herd immunity. In
summary, we believe that this method may represent an excellent
addition to COVID-19 Epidemiology and Public Health policies.
Materials and Methods
Cells
The human T-cell line Jurkat clone E6-1 was acquired from ATCC
(TIB-152) and was maintained in complete RPMI 1640 supplemented
with 5% fetal bovine serum (FBS, Sigma) in a 5% CO2 incubator.
Human embryonic kidney HEK293T cells (ATCC CRL-3216) and
human hepatocellular carcinoma HepG2 cells (ATCC HB-8065) were
maintained in DMEM (HEK293T) or RPMI (HepG2) supplemented
with 10% FBS in a 5% CO2 incubator. HEK293T cells expressing
ACE2 were generated by lentiviral transduction with vector CSIB and
selection in blasticidin S (Robbiani et al, 2020) All cell lines were
routinely tested for the absence of mycoplasma.
Lentiviral vector and Jurkat cell transduction
To express the full-length spike S protein of SARS-CoV-2, we used
the lentiviral vector based on the epHIV-7 plasmid that contains the
truncated version of human EGFR (huEGFRt) that lacks the domains
essential for ligand binding and tyrosine kinase activity described in
Wang et al (2011).
For transduction, lentiviral-transducing supernatants were
produced from transfected packaging HEK-293T cells as described
previously (Martinez-Martin et al, 2009). Briefly, lentiviruses were
obtained by co-transfecting plasmids pCMV-dR (gag/pol) and using
the JetPEI transfection reagent (Polyplus Transfection). Viral super-
natants were obtained after 24 and 48 h of transfection. Polybrene
(8 µg/ml) was added to the viral supernatants prior to transduction
of Jurkat cells. A total of 3 × 105 Jurkat cells were plated in a P24
flat-bottom well in 350 µl of RPMI, and 350 µl of viral supernatant
were added. Cells were centrifuged for 90 min at 1,600 g and 32°C
and left in culture for 24 h. Transduced cells were selected by FACS
sorting 48 h later using the anti-EGFR antibody.
Human sera
A total of 54 human sera were obtained from volunteers that
contacted EMPIREO SL (www.empireo.es) for serological tests.
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Serum donors filled in a questionnaire to allow their clinical classifi-
cation according to the following parameters: asymptomatic, no
symptoms; mild, three or more of the following symptoms: non-
productive cough, hyperthermia, headache, odynophagia, dyspnea,
asthenia, myalgia, ageusia, anosmia, cutaneous involvement;
moderate, three or more of the above symptoms plus gastrointesti-
nal symptoms, or more than three of the above for seven or more
days; moderate–severe, three or more of the above symptoms plus
pneumonia; and severe, pneumonia requiring hospitalization and
intubation. A second set of 30 serum samples was obtained from
healthcare workers at the Intensive Care Unit of the Ramon y Cajal
Hospital in Madrid. Those workers have been routinely tested for
COVID-19 by PCR and resulted always negative. A third cohort of
52 serum samples was selected from the study “Immune response
dynamics as predictor of COViD-19 disease evolution. Implications
for therapeutic decision-making” from the Hospital Universitario La
Princesa approved by the Research Ethics Committee (no. #4070).
Of those, 40 sera samples were from COVID-19 patients diagnosed
by PCR. All 52 serum samples were previously screened with an
ELISA test for the SARS-CoV-2 RBD fragment of the S protein
(Martınez-Fleta et al, 2020). A fourth set of 52 serum samples were
collected between 2010 and 2018, before the COVID-19 pandemic
and stored at 80°C at the CBMSO. Those samples constitute the
pre-COVID group. Finally, a fifth cohort of 415 serum samples was
obtained from capillary blood of volunteers working at the CBMSO
in the period of June–October 2020. All participants provided writ-
ten consent to participate in the study which was performed accord-
ing to the EU guidelines and following the ethical principles of the
Declaration of Helsinki.
Flow cytometry
Jurkat-S cells were incubated for 30 min on ice with 1:50 dilu-
tions of human sera in phosphate-buffered saline (PBS), 1%
bovine serum albumin (BSA), and 0.02% sodium azide. Cells
were spun for 5 min at 900 g, and the pellet was resuspended in
PBS-BSA buffer and spun to eliminate the excess of antibody.
Two additional washes were carried out. The cell pellet was
finally resuspended in a 1:300 dilution of mouse anti-human IgG1
Fc-PE (Ref.: 9054-09, Southern Biotech) and a 1:500 dilution of
the Brilliant Violet 421TM anti-human EGFR Antibody (Ref.:
352911, BioLegend) in PBS-BSA. Samples were then washed, and
labeled cells were analyzed on a FACSCalibur or FACSCanto II
flow cytometer (Becton-Dickinson), and the data were analyzed
with FlowJo software (BD). For multiplexing, the following anti-
bodies were used (all from Cytognos, S.L.): FITC-labeled anti-
IgG1, PE-labeled anti-IgG2, APC-labeled anti-IgG3, APCC750
labeled anti-IgG4, PEcy7-labeled anti-IgM, and PerCPcy5.5-labeled
anti-IgA (for IgA1 and IgA2).
Automatic classification of samples
Flow cytometry data were saved as Flow Cytometry Standard (FCS)
files and imported into R (R Core Team, 2013) with the read.FCS
function of the flowCore (Ellis et al, 2017) R library. For selecting
the main cell population and removing death or aggregated cells, an
automatic gating over de SSC.A and FSC.A channels was done with
a robust model-based clustering using a t-mixture model with Box–
Cox transformation as implemented in the flowClust R library (Lo
et al, 2009). Selected cell population signals in FL2.A and FL7.A
channels was modeled as a multivariate normal distribution using
an expectation maximization algorithm for fitting mixtures of multi-
variate skew normal distributions as implemented in the
EMMIXskew library (Wang et al, 2009). Our Score for classifying
the samples as positive or negatives was the r(FL2.A,FL7.A) of the
co-variance matrix defining the multivariate normal distribution.
For fine-tuning of the cutoff point of the co-variance for the classifi-
cation of samples, we have used a set of training samples composed
of negative samples (pre-COVID-19), and samples pre-classified as
positive or negative based on alternative tests such as ELISA or
PCR. Additionally, we have enriched this pool with serial dilutions
of clearly positive samples, until no signal was observed. In total,
we have used 168 flow cytometry readings, which once ordered
according to the co-variance of the FL2.A and FL7.A channels, were
splitted into positive and negative classes, without error, using
0.024 as the cutoff point. Further on, we have used this threshold to
classify remaining samples, considering as negative those below
the threshold.
Commercial kits
The following commercial serological tests were assayed:
• Feal Test of Hangzhou Alltest Biotech, reference number
RPP25COV1925.
• Sienna Test of Salofa Oy, reference number 102221.
• BiosSynex Test of Biosynex Swiss, reference number SW40005.
• Vircell ELISA test of Vircell SL, reference number G1032.
• COVID-19 VIRCLIA IgM + IgA monotest, Vircell SL, reference
number VCM098.
ELISA
96-well plates (MaxiSorp NUNC-Immunoplate) were coated over-
night at 4°C with S1 (2 µg/ml) and were subsequently blocked
for 1 h with 1% BSA (Sigma). Coated plates were incubated with
the diluted sera for 1 h at room temperature. Bound antibodies
were detected by incubation with mouse anti-human IgG1
secondary antibody coupled to horseradish peroxidase (HRP;
Southern Biotech) diluted 1/6,000 in 1% BSA in PBS which was
then detected using an ABTS substrate solution (Invitrogen). The
OD at 415 nm was determined on a iMark microplate reader
(Bio-Rad). Serum from a healthy individual previous to COVID-19
was used as negative control.
Immunoprecipitation and Western blot
For surface biotinylation, 20 × 106 Jurkat-S cells were incubated
for 45 min on ice with 0.5 mg/ml of sulfo-NHS-biotin (Pierce) in
PBS supplemented with 0.1 mM CaCl2 and 1 mM MgCl2. After
washing, the cells were lysed in Brij96 lysis buffer (0.33% Brij96,
150 mM NaCl; 20 mM Tris–HCl pH 7.8; 10 mM iodoacetamide;
1 mM PMSF; 1 lg/ml aprotinin; 1 lg/ml leupeptin) and immuno-
precipitation was carried out with a mix of protein G beads and
anti-T2A antibody (anti-2A peptide, clone 3H4 monoclonal anti-
body cat #MABS2005, EMD millipore) and incubated overnight
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with rotation at 4°C. The bead-bound material was washed 5 times
and subjected to SDS–PAGE. The proteins recovered were then
transferred to a nitrocellulose membrane that was probed with
streptavidin–horseradish peroxidase (Southern Biotech), diluted
1:20,000. Binding of streptavidin–peroxidase was then visualized
using ECL(Pierce).
Neutralization assay with pseudotyped virus
Lentiviral supernatants were produced from transfected HEK-293T
cells as described previously (Martınez-Martın et al, 2009). Briefly,
lentiviruses were obtained by co-transfecting plasmids psPAX2
(gag/pol), pHRSIN-GFP, and either a truncated S envelope (pCR3.1-
St) (Robbiani et al, 2020) or VSV envelope (pMD2.G) using
the JetPEI transfection reagent (Polyplus Transfection). Viral super-
natants were obtained after 48 h of transfection. Polybrene (8 µg/
ml) was added to the viral supernatants prior to transduction of
ACE2+HEK293T cells. A total of 15 × 103 ACE2+ HEK293T cells per
well in a 96-well plate were seeded the day before transduction.
Serially diluted plasma was incubated with viral supernatant for 1 h
at 37°C prior addition to the cells. Cells were centrifuged for 70 min
at 1,600 g and left in culture for 48 h and then were resuspended
in PBS with 2% FBS and 5 mM EDTA and fixed with 2%
paraformaldehyde. GFP+ cells were then analyzed on a FACSCanto
II flow cytometer (Becton-Dickinson), and the data were analyzed
with FlowJo software (BD).
Formation of syncytia
To analyze the formation of syncytia between Jurkat-S and HepG2
cells, HepG2 cells were detached from the culture plate by
trypsinization and resuspended at a concentration of 3 × 106 cells/
ml in PBS. Jurkat-S cells were collected by centrifugation and resus-
pended in PBS at the same concentration. HepG2 cells were labeled
with Cell Trace Far Red (CTFR, Invitrogen) for 5 min at 37°C in
PBS; Jurkat-S were labeled with CFDA-SE (CFSE, Invitrogen) under
the same conditions. Both dyes were used at a final concentration
of 5 lM. Labeling was stopped by adding complete medium and
the cells washed with medium and finally mixed at different ratios
in complete RPMI medium + 5% FBS and plated overnight at 37°C.
Formation of syncytia was analyzed by flow cytometry by calculat-
ing the percentage of cells double positive for CFSE and CTFR.
Syncytia formation was confirmed by confocal microscopy. Syncytia
was selected by FACS sorting and allowed to bind to poly-L-lysine-
coated glass for 30 min and fixed for 10 min at room temperature
with 4% paraformaldehyde. Cell nuclei were stained with 1 µg/ml
DAPI in PBS for 5 min, and finally, samples were mounted with
Prolong Antifade (Molecular probes). Samples were observed by
LSM 710 laser scanning confocal microscope. Image processing was
performed using Zen software.
Statistics
Unpaired two-tailed Student t-tests were used to compare statistical
significance between two groups of MFI values that followed a
normal distribution. A paired t-test was used to compare series of
dilutions of two samples. All data were analyzed using the
GraphPad Prism 7 software.
Serum samples were received coded from the providers, and
the experimentalists were blinded to their nature until all data
analysis was finalized. Sample analysis was carried out in dupli-
cate or triplicate, and all experiments were repeated a minimum
of two times.
Data availability
This study includes no data deposited in external repositories.
Jurkat-S cells are available for academic research upon request to
B. Alarcon.
Expanded View for this article is available online.
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Problem
Current serological tests for detection of antibodies to SARS-CoV-2 are
based on the use of recombinant fragments of proteins, including the
spike S protein, that do not reproduce the native form of the protein
in the context of the full virus or infected cells. This may lead to miss-
ing important antibodies that recognize conformational epitopes
present in the native forms.
Results
By expressing in a stable manner the S protein of SARS-CoV-2 and a
EGFR reporter construct on the surface of the human T lymphoblastic
leukemia cell line Jurkat, we have created a flow cytometry-based
method of detection of antibodies against the S protein that results
more sensitive, more specific, and more relevant for the detection of
functional neutralizing antibodies than those using recombinant
proteins.
Impact
The method will allow to assess in a precise manner the degree
of humoral immunity in human populations before and after
vaccination, allowing to evaluate how close we are to the sought herd
immunity.
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